Effects of conjugated fatty acid supplementation on anthropometric and insulin sensitivity factors in women with benign breast disease: a randomized controlled-clinical trial

Introduction: Health benefits of conjugated fatty acids (CFAs), particularly conjugated linolenic acid (CLnA), have recently attracted growing attention in a variety of obesity-related cancers including breast neoplasia. Method: Forty six pre-menopausal women with benign breast disease (BBD) were randomly divided into two groups: 1000 mg/day placebo oil-contained capsule+10IU vitamin E (n=23), and 1000 mg/day CLnA-contained oil (CLnAO) capsule+10 IU vitamin E (n=23). The mean treatment duration was 13 weeks. Anthropometric measures (weight, BMI, waist and hip circumference, waist to hip ratio, and body fat%(BF%)) were done at baseline, week 4, 8, and endpoint. Fasting serum was analysed for baseline and endpoint levels of insulin, C-Peptide, and glucose. Results: In an equal condition of physical activity and dietary intake, all patients showed a significant increase in BF%, with a higher elevation in placebos (P= 0.009 V.S P= 0.02). C-Peptide also showed a trend like that was seen forBF% (P=0.01 V.S P= 0.03). Additionally, a significant reduction was observed for glucose in both groups. When data were classified by median value of daily total calorie intake/body weight ratio (CWR), as a significant confounder for all anthropometric measures, placebos in high median CWR experienced a significant enhancement for C-eptide (0.04) and BF% (P= 0.002), whereas CLnAO group remained unchanged. Other variables showed a non-significant change in both CWR-subdivisions. Conclusion: Dietary supplementation with CLnAO in normal and overweight women with BBD, who used higher CWR, caused a remarkable improve in BF% and C-Peptide, as two manageable risk factors for later BC.

کلیدواژه ها:

breast neoplasia ، conjugated fatty acid